Trevi Therapeutics (TRVI) announced that it has commenced an underwritten public offering of $150M of shares of its common stock. All of the shares in the offering are being offered by Trevi. Morgan Stanley, Leerink Partners, Cantor, and Stifel are acting as joint book-running managers for the offering and Oppenheimer & Co. is acting as lead manager.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics: Positive Needham Conference Takeaways Reinforce Buy Rating and Favorable Risk‑Reward Profile
- Trevi Therapeutics price target lowered to $24 from $25 at JonesResearch
- Trevi Therapeutics Maps Phase III Path and Runway
- Trevi Therapeutics price target lowered to $18 from $19 at Morgan Stanley
- Trevi Therapeutics reports Q4 EPS (6c), consensus (10c)